Introduction
The EGFRvIII oncogenic mutation, a common genetic rearrangement of epidermal growth factor receptor (EGFR), is observed in astrocytic tumors and other systemic epithelial cancers and involves an in-frame deletion of 801 bp of the coding sequence to generate a constitutively active protein (reviewed in Kapoor and O'Rourke, 2003) . Expression of EGFRvIII in glioblastoma has been regarded as a negative prognostic indicator, and mediates resistance to EGFR-targeted tyrosine kinase inhibitors through drug-resistant activation of Akt (Learn et al., 2004; Heimberger et al., 2005) . Expression of EGFRvIII has been reported in breast, non-small-cell lung, ovarian and prostate carcinomas, but not in normal tissues, making it an attractive target for anticancer therapy (Garcia de Palazzo et al., 1993; Moscatello et al., 1995; Wikstrand et al., 1995; Kuan et al., 2001; Pedersen et al., 2001) . Therefore, proper elucidation of the role of different components of the EGFRvIII signalosome may be exploited for alternate treatment strategies.
SHP-2, a ubiquitously expressed SH2 domain-containing tyrosine phosphatase, has been implicated in a variety of signal transduction pathways elicited by growth factors, including EGF, cytokines, hormones, antigens and extracellular matrices (Feng, 1999; Yuan et al., 2003 Yuan et al., , 2005 . SHP-2 has been shown to execute its effect by interacting and binding to several signaling molecules including Grb2 (Minoo et al., 2003) , Gab1 (Kapoor et al., 2004b) , Gab2 and PLC-g (Boudot et al., 2002) , ErbB family receptors (Schulze et al., 2005) , PDGFRB (Rual et al., 2005) and focal adhesion kinase (FAK) (Retta et al., 1996; Wang et al., 2005; Tsutsumi et al., 2006; Guo et al., 2007) . Our previous report indicates that an association between SHP-2 PTPase and the Gab1 adapter protein is critical for the EGFR activation loop (Kapoor et al., 2004b) . We have recently showed that SHP-2 and its phosphatase activity are required for EGFRvIII-mediated transformation (Zhan et al., 2009) . Therefore, modulation of SHP-2 activity or its association with the activated receptor complex may regulate EGFRvIII-mediated oncogenic phenotypes.
Signal regulatory proteins (SIRPs) comprise a receptor family, the structure of which includes three extracellular immunoglobulin loop (immunoglobulin) domains (reviewed in Kapoor et al., 2004a) . Orthologs of human SIRPa1 are SHPS-1, MFR, p93, p84, BIT and MyD-1, based on the sequence homology in different mammalian species. The cytoplasmic tail of SIRPa1 receptors includes several immunoreceptor tyrosinebased inhibitory motifs. Various studies have linked SIRPa1 receptors to different biological processes, most notably cell growth and motility. We, along with others, have shown that wild-type EGFR (wtEGFR) and EGFRvIII have distinctly different patterns of ligand responsiveness, kinetics of internalization and transforming efficiency (Huang et al., 1997; Lorimer and Lavictoire, 2001; Zhan and O'Rourke, 2004) , suggesting that wtEGFR and EGFRvIII may interact differentially with SIRPa1 inhibitory receptors. Previously, we reported that SIRPa1 associates with SHP-2 to negatively regulate wtEGFR-mediated phosphatidylinositol 3-kinase (PI3-K) signaling and resulted in reduced transformation, cell migration and cell spreading, and enhanced apoptosis after DNA damage in human glioblastoma cells (Wu et al., 2000) . However, the exact molecular mechanism of inhibition is still unclear.
On the basis of its ability to bind SHP-2 and negatively modulate erbB receptor signaling, the SIRPa1 receptor system is particularly intriguing because of its role in inhibitory signaling. In this study, we used wellcharacterized glioblastoma cell lines to further study the effects of the SIRPa1 inhibitory receptor on the EGFRvIII-mediated phenotype. We show that enhanced expression and activation of SIRPa1 receptors inhibited EGFRvIII-mediated transformation and migration. We clearly show that SIRPa1 specifically targets EGFRvIII-induced MAPK pathways without affecting the PI3-K/Akt signaling axis, which is distinctly different from the effect observed in wtEGFRmediated transformation (Wu et al., 2000) . We show that SIRPa1 inhibits EGFRvIII-mediated phenotype by sequestering SHP-2 away from the EGFRvIII/Gab1/ SHP-2/Sos-1/Grb2/FAK complex, which is essential for EGFRvIII-mediated MAPK activation and transformation. Our data indicate that the SIRPa1 receptor differentially regulates SHP-2 phosphorylation at the Tyr542 and Tyr580 residues, resulting in the defective assembly of components of the EGFRvIII signalosome required for the activation of the MAPK pathway and the transforming phenotype. Collectively, our data suggest that modulation of SIRPa1 inhibitory receptor expression and/or function could be used as an adjunct to existing therapies for erbB-driven tumors, including glioblastomas and other epithelial malignancies.
Results

SIRPa1 overexpression downmodulates EGFRvIIImediated migration in human glioblastoma cells
In a previous study, we reported that SIRPa1 expression/activity was regulated by EGFR function or kinase activation (Kapoor et al., 2004a) . We have also reported previously that inhibitory SIRPa1 receptor interacts with SHP-2 through the PI3-K pathway to inhibit wt EGFR-mediated glioblastoma cell migration, survival and transformation (Wu et al., 2000) . However, the effects of SIRPa1 inhibitory receptor on EGFRvIIIexpressing glioblastoma cells are not understood. In this study, we investigated the role of SIRPa1 on EGFRvIII-mediated signalosome and phenotypes. We used U87MG.EGFRvIII stable subclones expressing SIRPa1 protein (U87MG.EGFRvIII/SIRPa1) to assess its effect on EGFRvIII phenotypes. Overexpression of SIRPa1 conferred a large, flattened morphology without prominent astrocytic processes when compared with U87MG.EGFRvIII/empty vector (EV) controls, suggesting a less-aggressive phenotype ( Figure 1a ). As expected, SIRPa1 overexpression downmodulated the transforming efficiency of EGFRvIII-expressing glioblastoma cells (Figure 1b) .
Our previous study and reports from other groups have shown that SIRPa1 is involved in the regulation of cell migration and motility (Wu et al., 2000; Motegi et al., 2003; Yan et al., 2004) . On the basis of these observations, we extended our study to assess the role of SIRPa1 receptor on tumor cell migration mediated by the constitutively active EGFRvIII oncoprotein. Enhanced migration mediated by EGFRvIII has been observed in many cell types (Pedersen et al., 2004; Sampson et al., 2008) and neural stem cells (Boockvar et al., 2003 (Boockvar et al., , 2005 . Interestingly, SIRPa1-overexpressing U87MG.EGFRvIII cells exhibited reduced migration in a transwell chamber migration assay, when compared with EV control cells (Figure 2) . Additionally, pharmacological inhibition of EGFRvIII by AG1478 (5 mM) completely abolished the migration of EGFRvIII/SIRPa1and EGFRvIII/EV subclones ( Figure 2 ). SIRPa1 overexpression downmodulates Erk1/2, p38MAPK and c-Jun terminal kinase activities, but not Akt, in EGFRvIII-expressing GBM cells To determine the downstream consequences of the diminished EGFRvIII phenotypes, as observed in SIRPa1 cells, we examined the activation status of various signaling pathways in U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 cells. Under normal serum conditions, we observed decreased Erk1/2, p38MAPK and c-Jun terminal kinase (JNK) phosphorylation in SIRPa1-overexpressing cells when compared with EV cells (Figure 3) . On the contrary, overexpression of the SIRPa1 protein did not affect the phosphorylation of Akt (Figure 3) . However, treatment with AG1478 (5 mM) reduced phosphorylation of Akt, indicating EGFRvIII-dependent Akt activation (Figure 3 ). Serum-starved cells were used as control to AG1478-treated cells. AG1478 treatment did not affect Erk1/2, p38MAPK and JNK phosphorylation in SIRPa1-overexpressing cells, suggesting that SIRPa1 may exert negative regulatory effects on Erk1/2, p38MAPK and JNK activities independent of EGFRvIII kinase activation (Figure 3) . Interestingly, SIRPa1 overexpression did not affect EGFRvIII phosphorylation (Figure 3 ).
EGFRvIII and SIRPa1 receptors exert counteractive effects
We have previously shown differential endogenous expression of SIRPa1 transcripts in different glioblastoma cell lines, with LN229 and U373MG cells showing the highest levels (Kapoor et al., 2004a) . To further understand the molecular interaction between SIRPa1 and EGFRvIII, we compared parental U87MG, LN229 and U373MG cells with their respective EGFRvIIIexpressing subclones for SIRPa1 expression. Interestingly, overexpression of EGFRvIII reduced the endogenous levels of SIRPa1 protein (Figure 4a ). Furthermore, RNAi-mediated silencing of EGFRvIII upregulated SIRPa1 expression in cell lines overexpressing EGFRvIII (Figure 4b ). To further substantiate these observations, we compared U87MG, LN229 and their respective EGFRvIII-expressing subclones for their ability to migrate across the transwell membrane. As expected, EGFRvIII-expressing cells showed increased migration when compared with parental cells (Figure 5a ). Moreover, we observed significantly reduced migration in LN229 (Po0.0001) and LN229.EGFRvIII (Po0.0005) cells when compared with their U87MG counterparts (Figure 5a ). To obtain further insight, we performed immunoprecipitation assays on LN229 and LN229.EGFRvIII cells using an anti-SHP-2 antibody. Western blot analyses showed an increased association of Gab1 and Grb2 with SHP-2 in EGFRvIII cells, compared with parental cells (Figure 5b) . However, the presence of a functional PTEN tumor suppressor protein in LN229 parental and EGFRvIII-expressing cells could have a major role in the downmodulation of tumor cell migration. To further justify the negative role of SIRPa1 on cell migration in the functional PTEN background, we applied RNAimediated silencing of SIRPa1 protein in LN229 and LN229.EGFRvIII cells. Interestingly, cells transfected with SIRPa1 siRNA showed significantly higher migration when compared with cells transfected with control siRNA (Figure 5c ). Furthermore, silencing of SIRPa1 expression upregulated Erk1/2 phosphorylation in both LN229 and LN229.EGFRvIII cells (Figure 5d ). However, there was a marginal reduction in Akt phosphorylation in LN229, but not in LN229.EGFRvIII, cells (Figure 5d ).
SIRPa1 overexpression sequesters SHP-2 away from EGFRvIII-induced Gab1/SHP-2 association We have previously shown that association between the Gab1 adapter and SHP-2 PTPase was critical for linking EGFR to NF-kB transcriptional activity through the PI3-kinase/Akt signaling axis in glioblastoma cells (Kapoor et al., 2004b) . To further understand the role of the molecular interaction between SIRPa1 receptors and the EGFRvIII/Gab1/SHP-2 complex in decreased MAPK activity and diminished tumor cell phenotypes, we subjected U87MG.EGFRvIII and U87MG.EGFRvIII/SIRPa1 (subclones 3 and 10) cells to immunoprecipitation assays using an anti-SHP-2 antibody. Immunoblot analysis showed a reduced association between SHP-2 and the activated EGFRvIII/Gab1 complex in SIRPa1-overexpressing cells when compared with EV controls (Figures 6a and b) .
There was an increase in the association between SHP-2 and Gab1 on EGF treatment in all the cells (100 ng SIRPa1 abrogates EGFRvIII/Grb2/SHP-2/Sos-1 association to downmodulate the glioblastoma cell phenotype To further explore the negative regulatory effect of the SIRPa1 receptor on EGFRvIII activation assembly, we performed immunoprecipitation analyses on U87MG.EGFRvIII cells and on SIRPa1-overexpressing U87MG.EGFRvIII subclones using an anti-EGFR antibody. The EGFRvIII immunocomplexes showed reduced recruitment of SHP-2 on EGFRvIII in SIRPa1-overexpressing cells (Figure 7a ), which is in agreement with the results obtained in Figure 6a . Interestingly, SIRPa1-overexpressing cells showed decreased association of Grb2 with EGFRvIII, Gab1, SHP-2 and guanine U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were cultured in medium with or without FBS. One of the serum-starved plates of each cell line was pretreated for 30 min with AG1478 (5 mM). Total cellular proteins (20 mg) were resolved by SDS-PAGE and immunoblotted with anti-PY20, anti-EGFR, antiphospho-Erk1/2, anti-Erk1/2, anti-phospho-p38MAPK, anti-phospho-JNK, anti-phospho-Akt, anti-Akt and anti-b-actin antibodies. nucleotide exchange factor, Sos-1, when compared with EV controls (Figure 7b) . Similarly, Sos-1 immunocomplexes in U87MG.EGFRvIII/SIRPa1 subclones showed reduced association of EGFRvIII and SHP-2, compared with EV controls (Figure 7c ). Moreover, lysates from SIRPa1-expressing cells showed reduced levels of active Ras when compared with EV controls (Figure 7d ).
SIRPa1 differentially regulates SHP-2 phosphorylation to reduce the glioblastoma-transforming phenotype The effect of tyrosyl phosphorylation on SHP-2 function has always been controversial. To investigate whether SIRPa1 modulates SHP-2 tyrosyl phosphorylation to affect EGFRvIII signaling, we performed western blot analyses on U87MG.EGFRvIII and U87MG.EGFRvIII/SIRPa1 cells to assess the phosphorylation status of SHP-2 at Tyr542 and Tyr580. Interestingly, SIRPa1-overexpressing subclones showed reduced SHP-2 phosphorylation at Tyr580 when compared with EV control (Figure 8a ). However, U87MG.EGFRvIII/SIRPa1 cells showed no change in phosphorylation at Tyr542 when compared with control cells (Figure 8a ). Treatment with AG1478 (5 mM) reduced phosphorylation of SHP-2 at Tyr542, but not at Tyr580 (Figure 8a ). To further justify that SIRPa1 modulates SHP-2 phosphorylation, we applied RNAimediated silencing in U373MG and U373MG.EGFRvIII cells to inhibit endogenous levels of SIRPa1 inhibitory receptors. Silencing of endogenous SIRPa1 receptor resulted in increased phosphorylation of SHP-2 at tyrosyl residues 542 and 580 in U373MG.EGFRvIII cells (Figure 8b ). However, U373MG cells showed an increase in SHP-2 phosphorylation at tyrosyl residue 542, with no detectable levels of P-SHP-2 (Tyr580) (Figure 8b ). Figure 6 SIRPa1 sequesters SHP-2 away from the EGFRvIII/Gab1 complex. (a) Cell lysates from U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were subjected to immunoprecipitation with anti-SHP-2 antibody, followed by SDS-PAGE and immunoblotting with anti-PY20 and anti-SHP-2 antibodies. (b) U87MG.EGFRvIII/EV and U87MG.EGFRvIII/ SIRPa1 (clones 3 and 10) cells were serum starved for 24 h and subsequently either stimulated with EGF (100 ng/ml) or left unstimulated. Cell lysates were subjected to immunoprecipitation with anti-SHP-2 antibody, followed by SDS-PAGE and immunoblotting with anti-PY20, anti-Gab1, anti-SIRPa1 and anti-SHP-2 antibodies. (c) U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were cultured in medium with or without FBS. One of the serum-starved plates of each cell line was pretreated for 30 min with AG1478 (5 mM). Total cellular proteins (20 mg) were resolved by SDS-PAGE and immunoblotted with anti-phospho-Gab1, anti-Gab1 anti-b-actin antibodies. The intensity of the bands was measured by ImageJ software and represented as a percentage of U87MG.EGFRvIII cells in the upper panel. The lower panel values represent the ratio of band intensity of phospho-Gab1 to total Gab1. SIRPa1 mediates FAK dephosphorylation to exert an inhibitory effect on EGFRvIII-mediated migration and transformation FAK is a non-receptor cytoplasmic tyrosine kinase that modulates various cell functions, including survival, proliferation, migration and angiogenesis (Guan, 1997; Hanks and Polte, 1997; Mitra and Schlaepfer, 2006) . In this study, we showed that SIRPa1-overexpressing glioblastoma cells exhibited reduced phosphorylation of FAK at tyrosyl residues 397, 576/577 and 925 when compared with EV controls (Figure 9a ). Interestingly, there was no inhibitory effect on Src phosphorylation in SIRP-expressing cells, suggesting that SIRPa1 may exert site-specific regulation of FAK to inhibit the EGFRvIII phenotype, and that this may be independent of Src phosphorylation (Figure 9a ). FAK and Src exhibited constitutive phosphorylation in serum-starved SIRPa1-overexpressing cells (Figure 9a ). However, phosphorylation of FAK and Src was completely inhibited by treatment with AG1478 (5 mM) (Figure 9a ).
To further explore the mechanistic interaction between SIRPa1 and FAK, we performed immunoprecipitation assays on U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 subclones using an anti-FAK antibody. Interestingly, immunocomplexes from SIRPa1-overexpressing cells showed reduced association between FAK and EGFRvIII, Grb2, SHP-2 and Sos-1, compared with empty controls (Figure 9b) . Similarly, immunoprecipitation analyses using an anti-EGFR antibody showed reduced EGFRvIII/FAK association (Figure 9c ).
Discussion
The SIRPa1 receptor has been shown to positively (Oh et al., 1999; Eminaga and Bennett, 2008) or negatively (Kharitonenkov et al., 1997; Dong et al., 2008) regulate MAPK pathways after stimulation of many different receptors, including EGFR and the insulin receptor. We have reported previously that the inhibitory SIRPa1 receptor interacts with SHP-2 through the PI3-K pathway to inhibit wtEGFR-mediated glioblastoma cell migration, survival and transformation (Wu et al., 2000) . In this study, we studied the effect of the SIRPa1 inhibitory receptor on EGFRvIII-mediated signaling. We show that transforming efficiencies of SIRPa1-expressing U87MG.EGFRvIII subclones were significantly reduced in soft agar assays. Furthermore, SIRPa1-overexpressing cells showed reduced motility as compared with EV controls, suggesting that SIRPa1 Figure 7 SIRPa1 interferes with the EGFRvIII/Grb2/Sos-1/SHP-2 association to inhibit glioblastoma phenotypes. Cell lysates from U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were subjected to immunoprecipitation with anti-EGFR (a), anti-Grb2 (b) and anti-Sos-1 (c) antibodies, followed by SDS-PAGE and immunoblotting with anti-SHP-2, anti-Grb2, anti-Sos-1, anti-Shc, anti-EGFR, anti-Gab1 and anti-PY20 antibodies. (d). Cell lysates from U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were subjected to Ras activation assay as described in Materials and methods. SIRPa1-expressing cells show reduced Ras activity when compared with U87MG.EGFRvIII controls. Lane 4 shows strong Ras activity in positive controls. may modulate EGFRvIII-mediated signals to influence transformation efficiency and migration.
We next examined the downstream consequences of inhibitory effects of SIRPa1 receptor on EGFRvIII signaling. We previously showed that ectopic expression of a truncated erbB2 mutant in U87MG (wtEGFR) cells exhibited transcriptional upregulation of the SIRPa1 gene (Kapoor et al., 2004a) and led to an inhibition of transformation through the PI3-K/Akt axis without effecting the MAPK pathway (Kapoor et al., 2007) . On the contrary, our present data showed that the SIRPa1 receptor negatively regulates the MAPK pathway in U87MG.EGFRvIII cells without effecting the PI3-K/ Akt signaling axis, suggesting that the SIRPa1 inhibitory receptor differentially regulates wtEGFR and EGFRvIII signaling and SIRPa1 specifically targets EGFRvIII-mediated MAPK pathway activation. A previous study has shown that lysophosphatidic acidand sphingosine-1-phosphate-induced glioma migration was inhibited by pharmacological inhibitors of p38MAPK and JNK, suggesting that p38MAPK and JNK have a positive role in glioblastoma cell migration (Malchinkhuu et al., 2005) . Another study has shown that JNK2alpha2 is the major active JNK isoform and is involved in the promotion of proliferation and growth of human glioblastoma tumors (Cui et al., 2006) . SIRPa1 inhibition of p38MAPK and JNK in this study suggests that SIRPa1 may modulate EGFRvIII-induced migration and transformation by downregulating these MAPKs. Future studies will be focused to explore the mechanism of SIRPa1/p38MAPK/JNK regulation of EGFRvIII phenotypes. EGFRvIII transduces a more potent oncogenic signal and exhibits a more aggressive transforming phenotype than wtEGFR (Moscatello et al., 1996) . Our present data are consistent with the recent observation and model that strong EGFR stimulus directly activates Erk1/2 through Gab1/SHP-2 association, whereas weak or residual EGFR activation requires the PI3-K/Gab1/SHP-2 axis to activate the Erk1/2 pathway (Sampaio et al., 2008) .
To further justify the above observations, we used U373MG and LN229 glioblastoma cells, which express high endogenous levels of SIRPa1 receptor, compared with U87MG cells (Kapoor et al., 2004a) . Interestingly, expression of EGFRvIII oncoprotein in all cell lines downmodulates the expression of the SIRPa1 receptor. Similarly, RNAi-mediated inhibition of EGFRvIII upregulated SIRPa1 expression, supporting our previous report that downmodulation of EGFR signaling leads to transcriptional upregulation of the inhibitory SIRPa1 gene (Kapoor et al., 2004a) . Future studies will be focused on determining the mechanism by which EGFRvIII regulates SIRPa1 expression. Moreover, EGFRvIII-expressing cells showed increased migration, compared with parental cells. Further analysis showed increased association of SHP-2 with Gab1 and Grb2 in EGFRvIII-expressing cells, which is consistent with our previous report that SHP-2/Gab1 association is essential for EGFR signaling (Kapoor et al., 2004b) . Collectively, our data suggest that the two receptors exert counteractive effects on each other and that modulation of SIRPa1 expression or activation may be exploited to inhibit EGFR-driven glioblastoma phenotypes.
To further test our hypothesis that SIRPa1 confers a negative regulatory effect, we used SIRPa1-specific siRNA to inhibit its endogenous expression in both LN229 and LN229.EGFRvIII cells and showed that inhibition of SIRPa1 receptors increased migration and Erk1/2 activity. Activity of Akt was marginally decreased in LN229 cells, but was not affected in LN229.EGFRvIII cells, suggesting that SIRPa1 modulates the EGFRvIII phenotype specifically through the MAPK pathway.
The present data support our previous findings (Kapoor et al., 2004a (Kapoor et al., , 2004b and show that SIRPa1 sequesters SHP-2 away from the EGFRvIII/Gab1 complex and that the EGFRvIII/Gab1/SHP-2 association may have an important role in modulating EGFRvIII signaling. However, expression of SIRPa1 did not affect Gab1 phosphorylation, suggesting that interaction of Gab1 with EGFRvIII and other binding partners such as PLC-g and the p85 subunit of PI3-K may not be affected by SIRP overexpression. This may explain why Akt was not affected in SIRPa1-overexpressing cells. More importantly, our data suggest that the regulation of Erk1/2 activity may involve a molecular interaction between SHP-2 and other members of the EGFRvIII signalosome besides Gab1.
We then further extended our study to determine the molecular components of the EGFRvIII signalosome altered by SIRPa1 overexpression. Earlier studies have shown that SHP-2 functions as an adapter molecule between the activated PDGFR and Grb2/Sos-1 complex, but its exact role in regulating the PDGF signal was not elucidated (Bennett et al., 1994; Li et al., 1994) . We believe that the role of SHP-2 in EGFR signaling pathways may be more complex than that of an adapter molecule. We previously showed that SHP-2-dependent Erk1/2 activation regulates phosphorylation of EGFRvIII, but not of wtEGFR, suggesting a coupling between SHP-2, MAPK and EGFRvIII signaling and cell survival phenotypes (Zhan and O'Rourke, 2004) . However, the exact molecular interaction between SHP-2 and EGFRvIII signaling is still not clear. A previous study suggested that SHP-2 modulates the relay signal from EGFR to Erk1/2 by a mechanism independent of Grb2, Sos-1 and Shc interactions (Shi et al., 2000) . On the contrary, our data showed that sequestering of SHP-2 by SIRPa1 inhibited the recruitment of Grb2 and Sos-1 to the EGFRvIII/Gab1 complex. This observation may indicate that SHP-2 is required for a Sos-1/Grb2 interaction with the receptor to transduce transforming signals to the MAPK pathway and that the SIRPa1 inhibitory receptor disrupts this important association to downmodulate the EGFRvIII phenotype.
The present data strongly support our previous findings and reports from other groups that SIRPa1 is one of the important binding partners of SHP-2 (Wu et al., 2000; Yan et al., 2004; Qin et al., 2006; Eminaga and Bennett, 2008) . However, it is unclear how SIRPa1 modulates SHP-2 activity to exert its regulatory effects. Figure 9 The SIRPa1 inhibitory receptor facilitates FAK dephosphorylation to regulate EGFRvIII-mediated phenotypes.
(a) U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were cultured in medium with or without FBS. One of the serum-starved plates of each cell line was pretreated for 30 min with AG1478 (5 mM). Total cellular proteins (20 mg) were resolved by SDS-PAGE and immunoblotted with anti-phospho-tyrosine-specific FAK (Tyr397; Tyr576/577; Tyr925), antiphospho-src (Tyr418) and anti-b-actin antibodies. (b) Cell lysates from U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were subjected to immunoprecipitation with anti-FAK antibody, followed by SDS-PAGE and immunoblotting with anti-SHP-2, anti-Grb2, anti-Sos-1, anti-EGFR and anti-FAK antibodies. (c) Cell lysates from U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 (clones 3 and 10) cells were subjected to immunoprecipitation with anti-EGFR antibody, followed by SDS-PAGE and immunoblotting with anti-FAK and anti-EGFR antibodies.
Previous studies showed that Tyr542 and Tyr580 are the major sites of SHP-2 tyrosyl phosphorylation and that Tyr542 is the major Grb2 binding site (Bennett et al., 1994; Araki et al., 2003) . However, others have suggested Tyr580 to be major Grb2 binding site (Keegan and Cooper, 1996; Vogel and Ullrich, 1996) . Furthermore, previous work showed that the single phosphorylation of Tyr542 of SHP-2 is sufficient to activate the MAPK pathway in living cells (Lu et al., 2001) . Our data showed that SIRPa1-expressing U87MG.EGFRvIII glioblastoma cells showed decreased phosphorylation at Tyr580 when compared with control cells. However, RNAi-mediated inhibition of SIRPa1 in U373MG cells upregulated SHP-2 phosphorylation only at Tyr542 residue, but affects both sites (Tyr542 and Tyr580) in U373MG.EGFRvIII cells. These results suggest that SIRPa1 inhibitory receptor may downregulate glioblastoma phenotypes by differentially dephosphorylating SHP-2 in different cell lines. An earlier report showed that phosphorylated Tyr542 and Tyr580 residues interact intramolecularly with the N-SH2 and C-SH2 domains, respectively, to relieve basal inhibition of its PTP activity (Lu et al., 2001) . Therefore, it has been suggested that tyrosine phosphorylation of SHP-2 could be more important in MAPK activation by stimulating PTP activity than by increasing SHP-2 binding to Grb2 (Lu et al., 2001; Dance et al., 2008) . Our data suggest that SIRPa1 differentially regulates SHP-2 phosphorylation without affecting EGFRvIII activation, which may affect its interaction with the EGFRvIII/Grb2/Sos-1 complex, and thereby downmodulates EGFRvIII phenotypes by inhibiting MAPK activation. We have recently shown that SHP-2 and its PTP activity are positively required for EGFRvIII-mediated transformation (Zhan et al., 2009) . This observation and our present data collectively suggest that SHP-2 phosphorylation, PTP activity and its association in the receptor assembly are essentially required for EGFRvIII-mediated phenotypes.
Earlier studies have shown that FAK is a substrate and downstream effector of SHP-2 and the dephosphorylation of FAK by SHP-2 results in increased migration and metastasis (Yu et al., 1998; Qi et al., 1999; Vadlamudi et al., 2002; Wang et al., 2005; Tsutsumi et al., 2006; Cetin et al., 2007; Guo et al., 2007) . On the other hand, increased FAK expression and activity has been reported to enhance transformation, invasion and malignant tumor phenotype (Benlimame et al., 2005; Madan et al., 2006; Aponte et al., 2008; Dai et al., 2008; Luo et al., 2009) . FAK has also been shown to activate the MAPK pathway through multiple pathways, including through the Src/SHP-2/SIRPa1(SHPS-1) axis (Takeda et al., 1998; Tsuda et al., 1998) . Our data show that SIRPa1 negatively regulates FAK activity, as evident from the decreased phosphorylation at its major tyrosine residues, which may possibly be involved in inhibiting EGFRvIII-mediated MAPK activation and transformation. Increased phosphorylation of FAK and Src in serum-starved SIRPa1-overexpressing subclones suggests that FAK and Src are constitutively phosphorylated by the EGFRvIII oncoprotein. Moreover, phosphorylation of Src was not affected by SIRPa1 expression, suggesting that Src may contribute to FAK phosphorylation in serum-deprived cells irrespective of SIRPa1 expression. We justified our hypothesis by demonstrating that SIRPa1-expressing cells showed reduced association of FAK with EGFRvIII, SHP-2, Grb2 and Sos-1, compared with EV controls. Our data suggest that FAK activation and interaction may be important for EGFRvIII signaling and the SIRPa1 receptor may exerts its negative regulatory effect by targeting multiple components of the EGFRvIII signalosome to inhibit the transformed phenotype. On the basis of previous observations on SHP-2/FAK interaction, our present data suggest that FAK may be dephosphorylated by SHP-2 PTPase to modulate glioblastoma transformation and migration. However, the exact mechanism is still unclear and will be explored in future experiments.
Our present data on EGFRvIII-mediated signaling in glioblastoma cells are most consistent with a model (Figure 10 ) in which the constitutively activated EGFRvIII oncoprotein recruits Gab1, Grb2, SHP-2, Sos-1 and FAK, leading to the activation of the MAPK pathway and induction of increased transformation and migration. Overexpression or functional activation of the SIRPa1 inhibitory receptor sequesters SHP-2 away from the EGFRvIII signalosome. It exerts differential dephosphorylation of SHP-2 at Tyr542 and Tyr580 residues, which may account for its reduced interaction with Grb2, and then recruitment of Sos-1 to the Grb2/ SHP-2 complex is hindered. Concurrently, SIRPa1/ SHP-2 may have a part in the dephosphorylation of FAK and its reduced interaction with the EGFRvIII/ SHP-2/Grb2/Sos-1 signaling module. The reduced receptor interactions may result in decreased recruitment of Sos-1 to the membrane, followed by downregulation of the Erk1/2 pathway and inhibition of transformation and migration. SIRPa1 also downmodulates the activation of the p38MAPK and JNK pathways, which may have an important role in EGFRvIII-mediated phenotypes. The inhibition of multiple signaling components by AG1478 in our model justifies that inhibition of glioblastoma cell migration and transformation by SIRPa1 is EGFRvIII specific.
Taken together, our results show that SIRPa1 inhibitory receptors dephosphorylate and sequester SHP-2 away from the receptor complex, which may be a critical event for the efficient relay of EGFRvIII oncogenic signals in glioblastoma cells. Therefore, elucidation of mechanisms upregulating inhibitory SIRPa1 receptor endogenous expression and/or function could be used as an adjunct to existing therapies for erbB-driven tumors, including glioblastomas and other epithelial malignancies.
Materials and methods
Antibodies and other reagents
The following antibodies were used: anti-phosphotyrosine (PY20), anti-EGFR, anti-Sos-1, anti-Grb2, anti-Shc, anti-FAK and anti-SHP-2 antibodies, obtained from Santa Cruz, CA, USA. The anti-SIRPa1 antibody was kindly provided by Dr Gibbes R Johnson (Food and Drug Administration, Bethesda, MD, USA). The other antibodies used were the following: anti-Akt, anti-phospho-Akt, anti-phospho-Gab1 (Tyr627, #3231 and #C32H2), anti-phospho-SHP-2 (Tyr580) and anti-phospho-FAK (Tyr397, Tyr576/577, Tyr925) antibodies from Cell Signaling, Danvers, MA, USA; antiphospho-SHP-2 (Tyr542) from Epitomics, Burlingame, CA, USA; anti-phospho-Src (Tyr418) and anti-Gab1 antibodies from Millipore Corporation, Temecula, CA, USA; total Erk1/2, anti-phospho-Erk1/2, anti-phospho-p38MAPK and anti-phospho-JNK antibodies from Promega, Madison, WI, USA and anti-b-actin antibody from Sigma-Aldrich Corporation, St Louis, MO, USA. AG1478 (EGFR kinase inhibitor) was purchased from Calbiochem (San Diego, CA, USA).
Cell lines and culture
We used U87MG (PTEN mutant) glioblastoma cells either expressing EGFRvIII/EV or coexpressing EGFRvIII and SIRPa1 proteins to determine the exact molecular interaction between two receptors. Cells were cultured in Dulbecco's modified Eagle's medium (Cellgro, Herndon, VA, USA) with 10% fetal bovine serum (Hyclone, Ogden, UT, USA) at 37 1C in 95% air/5% CO 2 . U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 subclones were supplemented with 400 mg/ml G418 (Invitrogen, Carlsbad, CA, USA) and 40 mg/ml hygromycin B (Roche Diagnostics, Indianapolis, IN, USA) to maintain a stable expression of both EGFRvIII and SIRPa1 proteins. We also used LN229 (PTEN wild type), LN229.EGFRvIII (2 mg/ml Puromycin, EMD Chemicals Inc., Gibbstown, NJ, USA), U373MG (PTEN mutant) and U373MG. EGFRvIII to modulate the endogenous expression of SIRPa1. The U373MG.EGFRvIII cell line was kindly provided by Dr John A Boockvar (Cornell University, NY, USA). Figure 10 Model for the regulation of EGFRvIII-mediated signaling and phenotypes by SIRPa1 inhibitory receptors. EGFRvIII oncoprotein enhances transformation through a variety of pathways by constitutively recruiting and regulating several signal relay molecules. Current data show that EGFRvIII constitutively recruits Gab1, Grb2, SHP-2, Sos-1 and FAK, leading to the activation of the MAPK pathway and increased transformation and migration. Conversely, SIRPa1 sequesters SHP-2 away from the EGFRvIII/ Gab1 complex and exerts differential dephosphorylation of SHP-2 at Tyr542 and Tyr580 residues. Concomitantly, SIRPa1 inhibitory receptors modulate FAK dephosphorylation and its subsequent recruitment to EGFRvIII. This is accompanied by impaired recruitment of Grb2 and Sos-1 to the EGFRvIII receptor and then of Sos-1 to the membrane to activate the Ras/Raf/MAPK pathway, resulting in reduced EGFRvIII-induced transformation and migration. SIRPa1 also downmodulates the activation of p38MAPK and JNK pathways through unresolved mechanisms to regulate EGFRvIII-mediated phenotypes.
were selected using 40 mg/ml hygromycin for the stable expression of the SIRPa1 protein. A total of nine subclones were selected and assessed for EGFRvIII and SIRPa1 expression. We used two subclones (Cl.3 and Cl.10) in this study to represent a similar effect of SIRPa1 on the EGFRvIIImediated phenotype, as observed with other clones.
The siRNAs were transfected using Lipofectamine RNAi-MAX transfection reagent according to the manufacturer's recommended reverse transfection protocol (Invitrogen). The siRNA sequences are provided in the Supplement section.
Soft agar assays U87MG.EGFRvIII/EV and U87MG.EGFRvIII/SIRPa1 subclones were trypsinized and subjected to anchorage-independent transformation assays as described earlier (Kapoor et al., 2007) .
Transwell cell migration assay A transwell migration assay was performed according to the manufacturer's protocol (Cell Biolabs Inc., San Diego, CA, USA). The detailed protocol for migration assay is provided in the Supplement section.
Cell lysis, immunoprecipitation and immunoblotting Cells were subjected to immunoprecipitation and immunoblot analyses as described earlier (Kapoor et al., 2004b) . Bands on an immunoblot were quantified using ImageJ software acquired from http://rsb.info.nih.gov/ij/index.html.
Ras activation assay
The Ras activation assay was performed according to the manufacturer's protocol (Cell Biolabs Inc.). The detailed protocol of the Ras activation assay is provided in the Supplement section.
Statistical analysis
The statistical significance of differences between mean values was assessed with two-sample Student's t-test analysis. The minimum level of statistical significance was set at 0.05. Unless otherwise stated, all data are representative of at least three independent experiments.
